×
About 141,736 results

ALLMedicine™ Schizophrenia Center

Research & Reviews  67,083 results

Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophren...
https://doi.org/10.1017/S003329172000478X
Psychological Medicine; Huang LY, Jackson BS et. al.

Feb 24th, 2021 - Antisaccade tasks can be used to index cognitive control processes, e.g. attention, behavioral inhibition, working memory, and goal maintenance in people with brain disorders. Though diagnoses of schizophrenia (SZ), schizoaffective (SAD), and bipo...

Neurodevelopmental Trajectories and Psychiatric Morbidity: Lessons Learned From the 22q...
https://doi.org/10.1007/s11920-021-01225-z 10.1136/adc.2003.026880 10.1002/(SICI)1096-8628(19980710)81:4<328::AID-AJMG10>3.0.CO;2-N 10.1001/archpsyc.56.10.940 10.1097/00005053-199408000-00010 10.1002/ajmg.1320420131 10.1002/ajmg.a.40387 10.1016/j.neuron.2010.10.003 10.1038/mp.2017.161 10.1176/appi.ajp.2013.13070864 10.1192/bjp.2018.258 10.1038/s41436-019-0603-1 10.1192/bjp.bp.113.132324 10.1038/nature09552 10.1001/jamapsychiatry.2019.4779 10.1093/schbul/sbx005 10.1007/s11920-008-0026-1 10.1176/appi.ajp.160.9.1580 10.1016/j.schres.2014.01.020 10.1016/j.schres.2012.04.020 10.1016/j.schres.2016.12.023 10.1017/S0033291713001669 10.4088/JCP.13049su1c.04 10.1016/j.schres.2018.10.014 10.1002/wps.20347 10.1001/jamapsychiatry.2013.269 10.1001/jamapsychiatry.2016.3939 10.1176/appi.ajp.2013.13070864 10.1016/j.jaac.2015.03.016 10.1186/s13229-020-00338-1 10.1007/s00787-010-0092-x 10.1097/01.chi.0000228131.56956.c1 10.1176/appi.ajp.2009.09071016 10.1097/WCO.0b013e32835f1a30 10.1097/WCO.0b013e328352dd58 10.1186/gm546 10.1186/s11689-019-9267-z 10.1093/hmg/ddz166 10.1159/000438708 10.1093/hmg/ddy028 10.1002/ajmg.a.40359 10.1038/s41398-018-0354-9 10.1371/journal.pone.0173944 10.1176/appi.ajp.2017.16121417 10.1002/ajmg.a.40494 10.1038/s41586-018-0566-4 10.1001/jamapsychiatry.2018.0039 10.1016/S2215-0366(19)30123-3 10.1534/g3.115.021345 10.1176/appi.ajp.2019.19080825 10.3389/fneur.2014.00238 10.1038/mp.2016.150 10.1126/science.1253895 10.1038/nm.4240 10.1038/s41467-020-14628-y 10.1093/schbul/sby025 10.1016/j.jpsychires.2019.04.011 10.1038/npjschz.2016.3 10.1002/ajmg.a.38500 10.1002/pd.4935 10.1002/ajmg.a.38665 10.3389/fpsyt.2020.00646 10.1001/jamapsychiatry.2014.2671 10.1192/bjp.bp.116.195651 10.1076/0929-7049(199912)05:04;1-R;FT230 10.1016/j.schres.2006.04.007 10.1111/j.1365-2788.2007.00955.x 10.1038/mp.2014.105 10.1002/ajmg.b.32441 10.1016/j.ridd.2014.08.034 10.1001/jamapsychiatry.2014.2147 10.1038/s41467-018-04362-x 10.1192/bjp.bp.111.097139 10.1002/ajmg.c.31435 10.1001/2013.jamapsychiatry.43 10.1001/jamapsychiatry.2017.4327 10.1007/s11920-996-0038-7 10.1001/jamapsychiatry.2017.0312 10.1001/jamapsychiatry.2013.155 10.1176/appi.ajp.2019.19050527 10.1080/13668250.2011.572548 10.1111/jir.12117 10.1016/j.jpeds.2011.02.039 10.1016/j.jpsychires.2014.03.021 10.1093/schbul/sbv023 10.1016/S2215-0366(17)30078-0 10.1016/S0006-3223(99)00114-6 10.1016/j.physrep.2005.10.009 10.1177/0145445503259830 10.1176/appi.ajp.2008.07081242 10.1176/appi.ajp.2009.09040574 10.1016/j.cell.2012.02.039 10.1016/S0022-3476(65)82145-X
Current Psychiatry Reports; Fiksinski AM, Schneider M et. al.

Feb 24th, 2021 - The 22q11.2 deletion syndrome (22q11DS) is associated with a broad spectrum of neurodevelopmental phenotypes and is the strongest known single genetic risk factor for schizophrenia. Compared to other rare structural pathogenic genetic variants, 22...

A Pilot Study of Switching Electroconvulsive Therapy for Patients With Treatment Resist...
https://doi.org/10.1097/YCT.0000000000000747
The Journal of ECT; Tan XW, Oon LK et. al.

Feb 24th, 2021 - A Pilot Study of Switching Electroconvulsive Therapy for Patients With Treatment Resistant Schizophrenia or Mood Disorder.|2021|Tan XW,Oon LK,Tsang YYT,Ong HS,Tor PC,|

Circular inference predicts nonuniform overactivation and dysconnectivity in brain-wide...
https://doi.org/10.1016/j.schres.2020.12.045
Schizophrenia Research; Bouttier V, Duttagupta S et. al.

Feb 23rd, 2021 - Schizophrenia is a severe mental disorder whose neural basis remains difficult to ascertain. Among the available pathophysiological theories, recent work has pointed towards subtle perturbations in the excitation-inhibition (E/I) balance within di...

Vocalizing and singing reveal complex patterns of corollary discharge function in schiz...
https://doi.org/10.1016/j.ijpsycho.2021.02.013
International Journal of Psychophysiology : Official Jour... Ford JM, Roach BJ et. al.

Feb 23rd, 2021 - As we vocalize, our brains generate predictions of the sounds we produce to enable suppression of neural responses when intentions match vocalizations and to make adjustments when they do not. This may be instantiated by efference copy and corolla...

see more →

Guidelines  45 results

The American Psychiatric Association Practice Guideline for the Treatment of Patients W...
https://doi.org/10.1176/appi.ajp.2020.177901
The American Journal of Psychiatry; Keepers GA, Fochtmann LJ et. al.

Sep 1st, 2020 - The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.|2020|Keepers GA,Fochtmann LJ,Anzia JM,Benjamin S,Lyness JM,|methods,methods,methods,classification,therapeutic use,diagnosis,therapy,

CAPLYTA® (lumateperone) | Now Approved | caplyta.com‎
https://www.caplyta.com/‎

Jan 13th, 2020 - Learn about a new treatment. See full safety information, PI, and boxed warning. Get information about this orally administered capsule. Press Release. Prescribing Information. MOA. Important Safety Info. Dosing & Administration.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated r...
https://doi.org/10.1177/0269881119889296
Journal of Psychopharmacology (Oxford, England); Barnes TR, Drake R et. al.

Dec 12th, 2019 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, i...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C,et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treat...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch fo...

see more →

Drugs  1,625 results see all →

Clinicaltrials.gov  70,289 results

Quetiapine fumarate - quetiapine fumarate tablet, extended release-Lupin Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7803a290-91c0-4e7f-90b5-d2ff33a46cee

Feb 28th, 2021 - Quetiapine extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1)   Bipolar I disorder, manic or mixed episodes (1.2)   Bipolar disorder, depressive episodes (1.2)   Major depressive disorder, adju...

Quetiapine fumarate - quetiapine fumarate tablet-Lupin Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a951cd63-d329-47c9-965a-582fa73a07c6

Feb 28th, 2021 - Quetiapine fumarate tablet USP is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1)   Bipolar I disorder manic episodes (1.2)   Bipolar disorder, depressive episodes (1.2) Quetiapine tablets USP are indicated for the tr...

Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophren...
https://doi.org/10.1017/S003329172000478X
Psychological Medicine; Huang LY, Jackson BS et. al.

Feb 24th, 2021 - Antisaccade tasks can be used to index cognitive control processes, e.g. attention, behavioral inhibition, working memory, and goal maintenance in people with brain disorders. Though diagnoses of schizophrenia (SZ), schizoaffective (SAD), and bipo...

Neurodevelopmental Trajectories and Psychiatric Morbidity: Lessons Learned From the 22q...
https://doi.org/10.1007/s11920-021-01225-z 10.1136/adc.2003.026880 10.1002/(SICI)1096-8628(19980710)81:4<328::AID-AJMG10>3.0.CO;2-N 10.1001/archpsyc.56.10.940 10.1097/00005053-199408000-00010 10.1002/ajmg.1320420131 10.1002/ajmg.a.40387 10.1016/j.neuron.2010.10.003 10.1038/mp.2017.161 10.1176/appi.ajp.2013.13070864 10.1192/bjp.2018.258 10.1038/s41436-019-0603-1 10.1192/bjp.bp.113.132324 10.1038/nature09552 10.1001/jamapsychiatry.2019.4779 10.1093/schbul/sbx005 10.1007/s11920-008-0026-1 10.1176/appi.ajp.160.9.1580 10.1016/j.schres.2014.01.020 10.1016/j.schres.2012.04.020 10.1016/j.schres.2016.12.023 10.1017/S0033291713001669 10.4088/JCP.13049su1c.04 10.1016/j.schres.2018.10.014 10.1002/wps.20347 10.1001/jamapsychiatry.2013.269 10.1001/jamapsychiatry.2016.3939 10.1176/appi.ajp.2013.13070864 10.1016/j.jaac.2015.03.016 10.1186/s13229-020-00338-1 10.1007/s00787-010-0092-x 10.1097/01.chi.0000228131.56956.c1 10.1176/appi.ajp.2009.09071016 10.1097/WCO.0b013e32835f1a30 10.1097/WCO.0b013e328352dd58 10.1186/gm546 10.1186/s11689-019-9267-z 10.1093/hmg/ddz166 10.1159/000438708 10.1093/hmg/ddy028 10.1002/ajmg.a.40359 10.1038/s41398-018-0354-9 10.1371/journal.pone.0173944 10.1176/appi.ajp.2017.16121417 10.1002/ajmg.a.40494 10.1038/s41586-018-0566-4 10.1001/jamapsychiatry.2018.0039 10.1016/S2215-0366(19)30123-3 10.1534/g3.115.021345 10.1176/appi.ajp.2019.19080825 10.3389/fneur.2014.00238 10.1038/mp.2016.150 10.1126/science.1253895 10.1038/nm.4240 10.1038/s41467-020-14628-y 10.1093/schbul/sby025 10.1016/j.jpsychires.2019.04.011 10.1038/npjschz.2016.3 10.1002/ajmg.a.38500 10.1002/pd.4935 10.1002/ajmg.a.38665 10.3389/fpsyt.2020.00646 10.1001/jamapsychiatry.2014.2671 10.1192/bjp.bp.116.195651 10.1076/0929-7049(199912)05:04;1-R;FT230 10.1016/j.schres.2006.04.007 10.1111/j.1365-2788.2007.00955.x 10.1038/mp.2014.105 10.1002/ajmg.b.32441 10.1016/j.ridd.2014.08.034 10.1001/jamapsychiatry.2014.2147 10.1038/s41467-018-04362-x 10.1192/bjp.bp.111.097139 10.1002/ajmg.c.31435 10.1001/2013.jamapsychiatry.43 10.1001/jamapsychiatry.2017.4327 10.1007/s11920-996-0038-7 10.1001/jamapsychiatry.2017.0312 10.1001/jamapsychiatry.2013.155 10.1176/appi.ajp.2019.19050527 10.1080/13668250.2011.572548 10.1111/jir.12117 10.1016/j.jpeds.2011.02.039 10.1016/j.jpsychires.2014.03.021 10.1093/schbul/sbv023 10.1016/S2215-0366(17)30078-0 10.1016/S0006-3223(99)00114-6 10.1016/j.physrep.2005.10.009 10.1177/0145445503259830 10.1176/appi.ajp.2008.07081242 10.1176/appi.ajp.2009.09040574 10.1016/j.cell.2012.02.039 10.1016/S0022-3476(65)82145-X
Current Psychiatry Reports; Fiksinski AM, Schneider M et. al.

Feb 24th, 2021 - The 22q11.2 deletion syndrome (22q11DS) is associated with a broad spectrum of neurodevelopmental phenotypes and is the strongest known single genetic risk factor for schizophrenia. Compared to other rare structural pathogenic genetic variants, 22...

A Pilot Study of Switching Electroconvulsive Therapy for Patients With Treatment Resist...
https://doi.org/10.1097/YCT.0000000000000747
The Journal of ECT; Tan XW, Oon LK et. al.

Feb 24th, 2021 - A Pilot Study of Switching Electroconvulsive Therapy for Patients With Treatment Resistant Schizophrenia or Mood Disorder.|2021|Tan XW,Oon LK,Tsang YYT,Ong HS,Tor PC,|

see more →

News  2,661 results

Placenta's Role in Schizophrenia 'Bigger Than We Imagined'
https://www.medscape.com/viewarticle/945722

Feb 11th, 2021 - Schizophrenia-related genes in the placenta are predictive of the size of a baby's brain at birth and the rate of cognitive development. In a complicated pregnancy, such genes could raise the risk of developing schizophrenia later in life, new res...

Clozapine Still Underused in Refractory Schizophrenia
https://www.medscape.com/viewarticle/945771

Feb 11th, 2021 - With the exception of clozapine, the selection of an antipsychotic medication for acute treatment is driven by side effects. That's a key pearl of wisdom that Stephen R. Marder, MD, shared during a discussion of key criteria for choosing an antips...

No More Excuses: Vaccine Trials Prove Clinical Trial Diversity Is Doable
https://www.medscape.com/viewarticle/945400

Feb 9th, 2021 - The increased representation of minority patients in the COVID vaccine trials puts the rest of medicine to shame. For decades there have been calls to make clinical trials more diverse, but the 2015-2019 Drug Trials Snapshots Summary Report by the...

Antipsychotic Prescriptions Rising Much Faster than Psychosis Rates
https://www.medscape.com/viewarticle/945257

Feb 3rd, 2021 - While the rates of antipsychotic prescription in England doubled between 2007 and 2014, the odds of having psychotic symptoms rose only slightly over the same period, according to a new study published in  Schizophrenia Research. The researchers u...

'Alarming Finding' in Schizophrenia Patients With COVID-19
https://www.medscape.com/viewarticle/944844

Jan 27th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Schizophrenia spectrum disorder is associated with a significantly increased risked of dying from COVID-19, new research shows. Li's advice for cl...

see more →

Patient Education  33 results see all →